These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 2009531)
1. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Sklar MD; Prochownik EV Cancer Res; 1991 Apr; 51(8):2118-23. PubMed ID: 2009531 [TBL] [Abstract][Full Text] [Related]
2. Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation. Robert-Lézénès J; Meneceur P; Ray D; Moreau-Gachelin F Cancer Res; 1988 Jul; 48(14):3972-6. PubMed ID: 3164254 [TBL] [Abstract][Full Text] [Related]
3. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation. Prochownik EV; Kukowska J Nature; 1986 Aug 28-Sep 3; 322(6082):848-50. PubMed ID: 3528863 [TBL] [Abstract][Full Text] [Related]
4. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Van Waardenburg RC; Prins J; Meijer C; Uges DR; De Vries EG; Mulder NH Anticancer Res; 1996; 16(4A):1963-70. PubMed ID: 8712728 [TBL] [Abstract][Full Text] [Related]
5. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene. Riva C; el Khyari S; Rustum Y; Barra Y Anticancer Res; 1995; 15(4):1297-302. PubMed ID: 7654012 [TBL] [Abstract][Full Text] [Related]
7. Early down-regulation of c-myc in dimethylsulfoxide-induced mouse erythroleukemia (MEL) cells is mediated at the P1/P2 promoters. Kohlhuber F; Strobl LJ; Eick D Oncogene; 1993 Apr; 8(4):1099-102. PubMed ID: 8455938 [TBL] [Abstract][Full Text] [Related]
8. Effects of ornithine decarboxylase inhibition on c-myc expression during murine erythroleukemia cell proliferation and differentiation. Watanabe T; Sherman M; Shafman T; Iwata T; Kufe D J Cell Physiol; 1986 Jun; 127(3):480-4. PubMed ID: 3458709 [TBL] [Abstract][Full Text] [Related]
9. [Relationship between expression of c-myc and P53 genes and terminal differentiation during induced differentiation in Friend erythroleukemia cells]. Liu HT; Zhang HQ; Xue SB; Du CY; You JS; Song PG; Wang XL; Chen RX Shi Yan Sheng Wu Xue Bao; 1988 Sep; 21(3):311-9. PubMed ID: 3066081 [No Abstract] [Full Text] [Related]
10. Oncogene Expression and Cellular Radiation Resistance: A Modulatory Role for c-myc. Chiang CS; Sawyers CL; Mcbride WH Mol Diagn; 1998 Mar; 3(1):21-27. PubMed ID: 10096954 [TBL] [Abstract][Full Text] [Related]
11. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Ma Y; Yuan RQ; Fan S; Hu C; Goldberg ID; Laterra JJ; Rosen EM Anticancer Drugs; 2006 Aug; 17(7):733-51. PubMed ID: 16926624 [TBL] [Abstract][Full Text] [Related]
12. Multiple fractions of gamma rays do not induce overexpression of c-myc or c-Ki-ras oncogenes in human cervical carcinoma cells. Osmak M; Sorić J; Matulić M Neoplasma; 1993; 40(6):359-62. PubMed ID: 8289968 [TBL] [Abstract][Full Text] [Related]
13. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
14. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215 [TBL] [Abstract][Full Text] [Related]